Personalized Oncogenomics (POG) Program of British Columbia

ConditionsMetastatic Cancers Advanced Cancers Cancers That Cannot be Treated With Curative Intent

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-85

SponsorBritish Columbia Cancer Agency

About this trial

The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.

Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.

Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.

ECOG PS 0 or 1.

Disqualifiers

Unable or unwilling to consent to the above tissue and blood requirements.

Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.

Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.

Unwilling to receive medically actionable findings (germline and/or somatic).

Trial design

Design model

Single group

Treatments tested in this trial

Genome sequencing
Genetic
Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis

Treatment groups

5,000 Participants

are divided into 1 treatment group

Group A: Genome SequencingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Influence of genomic data on clinical decision-making

This outcome will allow us to study how often in-depth genomic data impacts on clinical decision-making in a general oncology population. It will help describe how useful or important this sort of data is in daily practice.

Time frame

5 years

Cataloging of cancer genomes

Accumulation of genomic information linked to treatment/outcome data will greatly enhance our knowledge and understanding of cancers and response to treatment.

Time frame

5 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

British Columbia Cancer Agency

Lead sponsor

BC Cancer Foundation

Collaborator

Source ClinicalTrials.gov

Apply now